MRT 6160
Alternative Names: MRT-6160Latest Information Update: 04 Jul 2024
At a glance
- Originator Monte Rosa Therapeutics
- Class Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action Proto oncogene proteins c vav degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 27 Jun 2024 Monte Rosa Therapeutics submits an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for MRT 6160
- 27 Jun 2024 Monte Rosa Therapeutics plans a proof of concept clinical trial for Ulcerative colitis and Rheumatoid arthritis
- 14 Jun 2024 Pharmacodynamics data from preclinical trial in Autoimmune disorders released by Monte Rosa Therapeutics